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INTRODUCTION 
 
 
                                  1. INTRODUCTION 
 
 Acute poisoning by organophosphosphorous Pesticides (OP) has reached 
epidemic proportions in most parts of the world, particularly in developing agrarian 
countries, where the toxicity of available poisons and paucity of appropriate medical 
facilities ensure a high fatality rate. 
 
 Their ease of access and socio–cultural factors plays important role in choice of 
OP as a self-poison and the incidence is higher in young economically active group with 
a common fatality ratio of 20% [1,2]. 
 According to WHO, world wide estimates of pesticide poisoning number             
3 million each year, with 2 million hospitalized from suicide attempts and 2,20,000 
deaths, the majority of which are actually intentional.   
 
 Poisoning due to occupational exposure, accounted for about one fifth of the 
incidents, with a fatality ratio of less than 1%.  More than 90% of the non-occupational 
incidents were suicidal, with a fatality rate more than 10% and the majority of the 
subjects are young males. 
 Accidental exposures accounted for 8-10% of the incidents and homicidal use 
(less than 1%) were other forms of poisoning.  The reported over all mortality following 
OP insecticide poisoning varies from 4-30% in different countries and institutions [4].  
 In India, OP compounds cause more self-poisoning deaths in southern and central 
India. In Northern India, aluminum phosphide causes most deaths with a fatality ratio  
 
over 90%. Other Pesticides used for self –poisoning include carbamates, Organochlorines 
and pyrethroids. [5 Organophosphorous compounds are principally used as pesticides, and 
their exposure is highly prevalent in developing countries.  Toxic effects of OPs are 
associated with significant morbidity and mortality and are a major global clinical 
problem. 
  
Occupational, suicidal (or) homicidal exposure to OPs produces a characteristic 
but treatable syndrome in humans thus, early recognition and timely intervention of 
toxicity from these compounds are of great importance, to emergency physicians and 
patients. 
    Case reports on acute pancreatitis following acute organophosphorus compound  
   
ingestion has been reported now and then, but regular studies with reference to  
 
Pancreatitis is not available in a serial manner. Hence an attempt was made to study  
 
Pancreatic involvement through biochemical means. 
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                                 2. REVIEW OF LITERATURE 
 
 Origins of serum amylase :    
           A variety of organs and secretions contain amylase activity, including pancreas, 
salivary glands, fallopian tubes and cyst fluid, testes, lungs, thyroid, tonsils, breast milk, 
sweat, tears, and some malignant neoplasms. The pancreas and salivary glands contain 
amylase concentrations several orders of magnitude greater than other organs. Because 
large quantities of amylase are required to maintain the serum amylase level, it is unlikely 
that the other listed organs are important sources of amylase. This is demonstrated clearly 
in electrophoresis studies of normal serum. Electrophoresis shows that serum amylase is 
of 2 main types, as follows: (1) P-type amylase from the pancreas, and (2) S-type 
amylase from the salivary glands. Fallopian tube secretions, tears, breast milk, and sweat 
have amylases with a similar electrophoretic mobility of salivary isoamylase. However, 
the salivary glands account for almost all of the S-type isoamylase. 
 Metabolic clearance of serum amylase : 
    The exact mechanisms of serum amylase metabolism are still not fully understood.  
Humans who have had a nephrectomy or have renal insufficiency have average serum  
amylase levels 50% higher than healthy individuals. Therefore, kidneys can be assumed    
to  play a major role in amylase metabolism. However, kidney is not the sole organ  
responsible for amylase clearance in humans. The extrarenal mechanisms of amylase  
clearance have not been defined. Because of the high serum amylase levels also observed  
in hepatic necrosis and cirrhosis, liver is thought to play a role in amylase metabolism. 
 
 Factors influencing serum amylase : 
                       Many conditions have been reported to cause hyperamylasemia. Although  
hyperamylasemia is commonly assumed to be due to the release of amylase into the  
serum by the diseased organ, the precise relationship between hyperamylasemia and an  
affecting condition is not entirely clear. Hyperamylasemia is most commonly a result of  
(1) pancreatitis or parotitis, (2) decreased metabolic clearance of amylase, or (3) amylase  
released from an involved organ.  
 
 CAUSES OF HYPERAMYLASEMIA:- 
 
Pancreatic diseases: 
       Acute or chronic pancreatitis is associated with increases in the P-type isoamylase. In  
acute pancreatitis, serum amylase is usually elevated 3-fold and then returns to normal by  
3-7 days. Patients with pancreatitis associated with hypertriglyceridemia or those  
with considerable acinar cell injury due to previous episodes of pancreatitis or chronic  
pancreatitis may not exhibit hyperamylasemia. Other reasons for hyperamylasemia that  
are associated with pancreatitis are pseudocysts, pancreatic ascites, pancreatic trauma,  
and choledocholithiasis. Pancreatic trauma can be a result of blunt trauma, abdominal or  
retroperitoneal surgery, or endoscopic retrograde cannulation of pancreatic duct (ERCP).  
Trauma related to ERCP is thought to result from the regurgitation of amylase into the  
blood, which may occur in 75% of ERCPs, but most have no evidence of pancreatic  
injury. A 3- to 4-times increase in serum amylase levels 4 hours after ERCP predicts the  
occurrence of complicating postprocedure pancreatitis. In patients presenting with  
biliary-type abdominal pain, a 3-fold increase in serum amylase levels that returns to  
normal within 48-72 hours suggests stone passage through the common bile duct. 
 
Salivary diseases: 
               Parotitis is associated with increases in the S-type isoamylase. Parotitis is  
usually caused by trauma or surgery to the salivary gland, radiation to the neck area  
involving the parotid gland and subsequently causing duct obstruction, or calculi of the  
salivary duct. Another cause of damage to the salivary gland is from chronic alcoholism.  
Salivary amylase levels are 3 times higher than normal in 10% of patients with  
alcoholism; this may be related to chronic liver disease. 
Decreased metabolic clearance: 
         Renal failure results in increased S-type and P-type isoamylases. Liver disease from  
hepatitis or cirrhosis also results in increased S-type and P-type isoamylases. 
Macroamylasemia 
 
       Macroamylasemia is a benign condition where the amylase molecule binds with a  
large complex molecule (e.g., immunoglobulin, polysaccharide), thereby prolonging its  
half life and decreasing renal clearance. About 2-5% of patients with hyperamylasemia  
have macroamylasemia. 
 
Intestinal disease: 
          Gut diseases, including mucosal inflammatory disease of the small intestine,  
mesenteric infarction, intestinal obstruction, appendicitis, and peritonitis, usually result in  
increased P-type isoamylase because of increased absorption of amylase from the  
intestinal lumen. Gut perforation leaks the contents into the peritoneum causing  
inflammation and absorption of amylase across the inflamed peritoneum. This can result  
in hyperamylasemia. 
Female reproductive tract disease: 
          Ruptured ectopic pregnancy, fallopian or ovarian cysts, and salpingitis can result in  
increased S-type isoamylase. 
Miscellaneous causes: 
        Ectopic amylase production by lung, ovary, pancreas, and colon malignancies;  
pheochromocytoma; thymoma; multiple myeloma (increased salivary amylase); and  
breast cancer (increased pancreatic amylase) are miscellaneous causes of  
hyperamylasemia. 
       Acidosis, which can be due to (1) ketoacidosis that results in increased S-type and P- 
type isoamylases or (2) nonketotic acidosis that results in increased S-type isoamylase,  
can cause hyperamylasemia. 
    Amylase increases may occur postoperatively, resulting in increased S-type and P-type  
isoamylases; however, an increase in salivary amylase is more common. This may occur  
after extracorporeal circulation or nonabdominal surgery (e.g., 30% of patients  
undergoing cardiac surgery have elevated S-type isoamylase). 
     Other causes of hyperamylasemia include pneumonia (increased salivary amylase),  
cerebral trauma, burns, abdominal aortic aneurysms (increased pancreatic amylase),  
drugs (increased salivary and/or pancreatic amylase), anorexia nervosa and bulimia  
(increased salivary amylase),  and organophosphate poisoning. 
      Rare cases of hyperamylasemia are reported in association with systemic lupus  
erythematosus (SLE), as well as ciprofloxacillin treatment. 
 
 LABORATORY SIGNIFICANCE : 
 
                    The most widely used application of serum amylase measurements is to  
support a diagnosis of acute pancreatitis. In acute pancreatitis, the serum amylase is  
increased at least 3-fold in approximately 75% of cases on the initial day of symptoms;  
then, it usually returns to normal by 3-7 days. The specificity of the test increases with  
higher levels of the enzyme. 
                    Serum amylase measurements are not very sensitive or specific for  
pancreatic injury because they may be normal in patients with preexisting acinar injury or  
chronic pancreatitis and because many other causes of hyperamylasemia are described  
earlier. One should remember that a patient with asymptomatic chronic hyperamylasemia  
almost never has pancreatic disease as the cause of the amylase elevation. In cases of  
mild elevations of serum amylase, other methods may be used to help determine the  
cause of hyperamylasemia. 
                     The amylase-to-creatinine clearance ratio (ACR) can help differentiate acute  
pancreatitis from other conditions. This ratio is calculated using the following equation: 
 
 
ACR = (amylase[urine] X creatinine[serum]) / (amylase[serum] X creatinine[urine])  
             X 100 
 
 
 
              
              An ACR of greater than 5% suggests acute pancreatitis. However, the  
ACR is also known to be increased in diabetic ketoacidosis and renal disease and after  
surgery. An ACR of less than 1% suggests macroamylasemia. Because findings of  
urinary amylase are relatively nonspecific, calculations for urinary amylase excretion  
have almost no clinical value. Generally, the ACR measurement has been abandoned,  
except to confirm a diagnosis of macroamylasemia,which is characterized by a low ACR. 
A lipase-to-amylase ratio of greater than 2 may suggest alcoholic pancreatitis, but it is not  
a reliable predictor of alcoholic pancreatitis. 
 
            Serum isoamylase measurements to determine S-type isoamylase, P-type  
isoamylase, or macroamylasemia are the best tests to use when the etiology of  
hyperamylasemia is obscure. 
 
2.1. ORGANOPHOSPHATES – A BACKGROUND 
  
 The clinical manifestations of OP Poisoning are caused by excessive synaptic 
accumulation of acetylcholine (ACh).  OP compounds, irreversibly inhibit the enzyme 
cholinesterase (ChE) resulting in excessive accumulation of ACh, leading to the paralysis 
of cholinergic transmission in the CNS, autonomic ganglia, parasympathetic nerve 
endings, some sympathetic nerve endings and neuromuscular junctions.   
 
 
 
 Basic structure  
 The anticholinesterase Organophosphate compounds (OPs) are the organic 
derivatives of phosphorous containing acids, with a basic structure of, 
          Z 
          ||       
                 R –    P – OH     
      | 
      R’ 
 
 
R= alkoxy group (methoxy (or) butoxy) 
R’= alkoxy (or) phenoxy group 
Z = Oxygen (or) sulfur 
Toxicokinetics 
 OP agents and carbamates are generally highly lipid soluble and hence may be 
systemically absorbed and can cause toxic effects within minutes after exposure.  They 
are well absorbed by inhalation, occular exposure, across any mucosal surface, the skin 
and throughout the gastrointestinal tract (GIT).  Skin exposure is extremely important, as 
many cases of toxicity occur after cutaneous exposure alone. 
            The onset, severity and duration of poisoning is determined by the degree, route 
of exposure, the lipid solubility and rate of metabolism of the particular compound and 
activation in liver, required before the compound is active. 
           Direct acting OP agents function to inhibit cholinesterase directly, and do not 
require bio-activation in the liver.  Indirect inhibitors require oxidation by the G1 mucosa 
and liver to active forms, which then inhibit ChE.  Most of the commonly encountered 
insecticides such as Malathion and Parathion are indirect agents and require bioactivation 
before manifesting toxicity.  The onset of clinical effects may be from 5 min to 24 hours 
post exposure. 
 Because OP agents are very fat soluble they may accumulate in the body’s fat 
stores which acts as a “reservoir”, prolonging elimination and toxic effects.  This has 
been reported for more lipophilic compounds such as Fenthion and Chlorfenthion.[3]. 
2.2. CHOLINESTERASE (ChE)  
  
         Cholinesterase is one of the many enzymes needed for the proper functioning of the 
nervous system.  It hydrolyses the ACh into choline and acetate .The choline formed is 
then recycled [7]. 
      
 
Acetylcholine  
    Cholinesterase 
    
       Choline  Acetate 
Types of ChE 
 A specific acetylcholinesterase AChE (or) true cholinesterase: - Found primarily 
in nervous tissue and erythrocytes. 
 Non – specific butyrylcholinesterase (BuChE) or pseudocholinesterase: - Present 
in plasma (or) serum and non- neuronal tissues [7].  
 Brain cholinesterase. 
 
 The pathological effects of organophosphates result from inhibition of ChE [both, 
RBC and pseudocholinesterase].  These are the markers of exposure, acute toxic effects 
and reflect actual activity at cholinergic nerve terminal [11].  
 
 In the acute phase of OP poisoning serum ChE activity is usually depressed with 
in a few hours to few days and is also restored to normal levels quickly.  About 3% of the 
population has a genetic variation manifested by a serum ChE deficiency.  Pregnancy, 
acute (or) chronic inflammatory conditions, malnutrition and liver disease are conditions 
that also affect serum ChE levels, but the depression caused by these conditions is not as 
great as that caused by organophosphate insecticides. 
 This level can vary widely from person to person.  A 50% reduction in ChE 
activity from the baseline may result in acute cholinergic symptoms of organophosphate 
exposure.  These values differ among laboratories, and the range is very wide, with a 
30% spread [35]. 
 
Pathophysiology of OP poisoning 
 
 OP pesticides inhibit AChE at muscarinic and nicotinic synapses by depositing a 
phosphory1 group at the enzymes active site to form a temporary covalent bond, this 
results in an accumulation of ACh and uncontrolled activation of cholinergic synapses.  
Over time, one of two processes will occur. The covalent bond may spontaneously cleave 
leaving the enzyme functional again.  This process may take up to 1,000 hours.  Mean-
while, the enzyme is prone to “Ageing” in its active state in which one of the “R” group 
may cleave non-enzymatically, leaving a hydroxyl group in its place.  ‘Aged’ AChE with 
its negatively charged phosphate can no longer be attacked by a negatively charged 
nucleophile, i.e. OH or an oximate group, and regeneration is no longer possible.  
Recovery of a functional pathway must wait until new ChE enzyme is manufactured, a 
process that may take weeks. This can take up to 3 months for RBC and several weeks 
for plasma ChE.  The time it takes for ageing to occur varies according to the specific 
pesticide, but takes no longer than 48 hrs,  Clinically, toxic effects of OP agents may 
persist more than a week[1,3].Oximes slows down “ageing” of the phosphorylated 
cholinesterase and binds to the OP agent, making it non reactive.  This results in ChE 
regeneration and a rise in serum levels of ChE [11]. 
 Mechanism of action of OP on AChE  
Reactions 
1. Inhibition of AChE by depositing a phosphoryl group at the enzyme’s active site. 
2. Regeneration of inactivated enzyme by removal of phosphoryl group. 
3. Ageing of inactive AChE. 
(OP) 
2.3. CLINICAL MANIFESTATIONS [3] 
Table.4. List of the primary sites and clinical effects caused by excess Ach 
stimulation 
PARASYMPATHETIC 
SYSTEM 
CENTRAL NERVOUS 
SYSTEM 
SKELETAL MUSCUES 
Termed “Muscarinic” Termed “nicotinic”. 
Low Heart Rate  Delirium Muscle weakness 
Bronchospasm Agitation Muscle Fasiculations 
 
Excessive oral secretions 
Seizures Muscle Rigidity 
Excessive Tearing  Syncope Muscle paralysis. 
Vomiting Apnoea  
Diarrhoea Dizziness/ vertigo  
Abdominal cramping Lethargy  
Salivation Hypotension  
Sweating Hypertension  
Constricted pupils (miosis)   
 
 In recent works, it has been reported children, particularly those under nine years 
of age, are unlikely to develop classic “muscarinic” signs of OP poisoning.  More often 
than not, younger children manifest “nicotinic” signs of poisoning.  The most common 
features in pediatric poisoning are CNS depression and hypotonia [3]. 
 
 
 
Triphasic syndrome following OP poisoning 
 There are three distinct phases following OP poisoning. 
i) – Initial Acute cholinergic crisis 
ii) – Intermediate syndrome (IMS) 
iii) – Delayed polyneuropathy 
 
i) Acute cholinergic crisis:  
 Accumulation of ACh occurs at nerve endings as AChE is inhibited leading  to 
‘cholinergic crisis’, in which there is an initial stimulation and eventual exhaustion of 
cholinergic synapses.  The clinical findings are a mixture of muscarinic effects resulting 
from the post ganglionic parasympathetic activity, nicotinic effects resulting from the 
accumulation of ACh at neuromuscular junctions and consequent depolarization and CNS 
effects causing initial excitation and subsequent inhibition of all CNS activity. 
 
 The Muscarinic symptoms of cholinergic excess are described by two common 
mnemonics.  
 DUMBELS     SLUDGE / B B B. 
- Diarrhoea     - Salivation 
- Urination      - Lacrimation 
- Miosis     - Urination 
- Bronchorrhoea     - Defecation 
- Bronchospasm    - GI symptoms 
- Bradycardia      - Emesis 
- Emesis     - Bronchorrhoeea 
- Lacrimation                                                  - Bradycardia 
- Salivation 
 Patients may have hypertension and tachycardia occurring due to ‘nicotinic’ 
actions rather than hypotension and bradycardia. The nicotinic receptors activated during 
acute intoxication lead to muscle paralysis.  Fasciculations may be seen and are a reliable 
sign of poisoning. 
 Severe intoxication may cause emotional irritability, mental obtundation, 
cognitive impairment, coma and convulsions because of CNS effects.  In the cholinergic 
phase, paralysis usually passes off with in 48–72 hrs, but complete clinical recovery may 
take up to a week after exposure to these compounds [13]. 
 
ii)  Intermediate Syndrome (IMS) 
            After the acute cholinergic phase, a second stage of weakness occurs 1-4 days 
later with (or) without a symptom free interval, and if left unrecognized, can lead to fatal 
respiratory depression. 
 IMS develops 12- 96 hours later exposure and reflects a prolonged action of ACh 
on the nicotinic receptors.  The clinical features are muscular weakness in the occular, 
neck, bulbar, proximal limb and respiratory muscles with occasional dystonic posturing, 
requiring mechanical ventilation in an intensive care unit for several days[17]. 
 The Respiratory failure may be due to aspiration of gastric contents excessive 
secretions, pneumonia and septicemia complicating adult respiratory distress 
syndrome[18] 
 The cranial nerve palsies are common.  The sensory functions characteristically 
remain normal and full recovery is evident in 4-18 days.   
 
The incidence of IMS in different studies has been reported to be between 20-68% and 
has been commonly associated with OPs, like Diazinon, Dimethoate, Methyl parathion, 
Methamidaphos, Monocrotophos, Fenthion and Ethyl parathion. 
 The development of IMS might be due to a conformational changes in the 
acetylcholine receptor altering the depolarizing neuromuscular block to a non – 
depolarization block, characterized by a fade on tetanic stimulation [45]. 
 
iii)  Organophosphate – Induced Delayed Polyneuropathy (OPIDPN) 
 
 OPIDPN is a less common clinical condition which occurs within a period of one 
week to 5 – 6 months of the ingestion of an OP compound, almost exclusively in patients 
with preceding acute cholinergic toxicity.  It is not associated with death but causes 
disability due to peripheral muscle weakness, recovery from which is not certain. 
 The neuropathy in OPIDPN  is typically a symmetrical sensorimotor  neuropathy 
with a distal predominance.  Initial symptoms are paresthesia in the lower limbs and pain 
in the calves followed by motor involvement of the lower limbs, manifested by leg 
weakness, foot drop and muscle hypotonia.  OPIDPN is motor predominant, and pure 
sensory neuropathy do not occur [9]. 
 OPIDPN might be due to phosphorylation of an enzyme Neuropathy Target 
Esterase (NTE) in the nerve tissue resulting in neurological dysfunction.  Modification of 
the structure of NTE initiates an irreversible polyneuropathy. This phosphorylated 
enzyme also undergoes ageing [4]. 
 
 
  
Table 3. Classification of Severity in Organophosphorous Poisoning (NAMBA) [9 
Type of poisoning Clinical definition 
LATENT POISONING 
NAMBA – I 
No clinical manifestations, Diagnosis depends on the 
estimation of SChE activity which is inhibited by 10-50% 
MILD POISONING, 
NAMBA –II 
The patient can walk but complains of Fatigue, head ache, 
dizziness, numbness of extremities, nausea and vomiting, 
excessive sweating and salivation, tightness in chest, 
abdominal Cramps or diarrhoea; SChE activity is 20-50% of 
normal value. 
MODERATE 
POISONING NAMBA – 
III 
The patient cannot walk and there is generalized weakness, 
speaking difficulty, muscular fasciculations, miosis and 
severe symptoms described above; SChE activity is 10 -20% 
of normal value. 
SEVERE POISONING 
NAMBA IV 
Unconsciousness, marked miosis and loss of pupil reflex to 
light, muscular fasciculations, flaccid paralysis, secretions 
from the mouth and nose, moist rales in the lungs respiratory 
difficulty and cyanosis; SchE activity is lower than 10% of 
normal value.  
 
 
 
 
  
2.4. LABORATORY INVESTIGATION 
 
 Diagnosis of cholinergic excess is largely clinical and requires early recognition 
of the syndrome and a highly observant clinical setting. 
 
1) Serum and Red Blood cell ChE activity  
To confirm the exposure to an OP agent and to monitor prognosis of the patient. 
A 50% reduction in the activity of the enzyme is considered confirmatory for OP 
poisoning.  An incremental response in enzyme activity is seen with treatment. 
 
2) Serum electrolytes, creatinine and urea 
  To assess the degree of volume depletion in the presence of muscarinic secretory 
losses from the pulmonary and alimentary tracts [15]. 
 
3) Blood Urea Nitrogen (BUN) Monitoring 
 To predict the development of relapse in OP poisoning.  Elevation from its normal 
range [8-20 mg/dl] is seen in acute poisoning [16]. 
   
4) Arterial Blood Gas (ABG) analysis  
 To assess the degree of hypoxia and / or hypercapnia in the presence of 
respiratory distress from pulmonary congestion [15]. 
5) Hyperglycemia (serum glucose) – It has been reported in many studies.  The 
increase in serum glucose is due to secondary release of catecholamines from the 
adrenal medulla [14]. 
6) Serum Amylase – Many case reports have shown a rise in serum Amylase level 
following ingestion of organophosphorus poison with or without the development of 
Pancreatitis. 
7) Leukocyte Number – Leucocytosis is a common finding in OP intoxication.  It helps 
to assess the prognosis and efficiency of treatment [17]. 
 
Imaging Studies 
Chest X-ray  
 For evaluating pulmonary edema (or) congestion. 
            CT/USG Abdomen to evaluate the pancreatic status.  
            CT scan of the head may be considered for patients with altered mental status [15]. 
Other Tests 
Electrocardiogram (ECG)  
 Useful for evaluating the rare dysrhythmias including atrial fibrillation, 
ventricular tachycardia and torsades de pointes (or) QT prolongation.[18] 
 
Treatment 
 Organophosphate poisoning is a serious condition that needs rapid diagnosis and 
intensive care support.  Patients who receive appropriate treatment immediately recover 
from acute toxicity. 
 
The main – stays of treatment are,  
 - Supportive care 
 - Atropine 
 - Oximes 
 - Benzodiazepines 
The supportive care treatment includes 
 * Gastric lavage 
 * Air way control 
 * Oxygenation 
 * Ventilation and  
 * Seizure management. 
 
2.5. DRUG THERAPY 
Atropine:- 
Category: - Physiologic antidote for antagonizing the muscarinic receptor mediated 
response. 
 
 Atropine antagonizes the excess AChE activity at muscarinic receptor mediated 
responses such as increased tracheobronchial secretions, excessive salivation and 
bronchoconstriction, but does not block nicotinic receptors hence a poisoned patient may 
have respiratory muscle – paralysis [19]. 
 
 Full and early atropinisation is an essential and simple part of an early 
management and a delay can result in death from central respiratory depression, 
bronchospasm, bronchorrhoea, severe bradycardia or hypotension [20]. 
 Targeted End – Points of Atropinisation [21]. 
 Clear lungs 
 Dry axillae 
 Systolic BP > 80mm Hg. 
 Heart rate > 80 /min 
 No miosis 
 Table 5. Atropine recommendations in major text books of internal medicines and 
national formularies [20] 
Source Recommended Regimen 
to attain Atropinisation 
Marker of Atropinisation 
Australian Medicines hand 
book 14th Edition, 2003. 
2 mg IV repeated until 
Atropinisation is achieved 
then infusion titrated 
against clinical effects. 
Abolish all secretions. 
British National Formulary 
Edition - 46, 2003 
2 mg repeated every 5 – 10 
min. IM (or) I.V according 
to severity.   
Dry Flushed skin, Dilated 
pupils, tachycardia 
Harrison’s Internal 
Medicine 
 Edition - 16, 2005 
0.5 – 2mg repeated every  
5-15 min. 
Dry secretions. 
WHO model formulary  
Edition - 1, 2002 
2 mg repeated every  
20-30 min 
Flushed early skin and 
tachycardia 
 
 
Atropine Toxicity:-  
 Excess atropine can cause atropine toxicity characterized by confusion, agitation, 
atropine induced hyperthermia and cardiac arrest [20]. 
 
Oximes:  
Category: Cholinesterase Reactivators. 
 Oximes are effective in treating nicotinic symptoms by reversing the phosphate –
ester bond formed between the OP and acetyl cholinesterase and these reactivates the 
enzyme.  It also prevents subsequent binding of insecticides to the AChE and accentuates 
therapeutic effects of atropine [25]. 
 
The oximes used are, 
 Pralidoxime (Currently and commonly used) 
 Obidoxime 
 Trimedoxime 
 Asoxime [10]. 
 
 Oximes are indicated in muscle weakness (especially respiratory muscle 
paralysis).  They must be used early in course of poisoning to be effective before the OP 
– AChE bond as aged.  It may help to prevent intermediate and delayed neuromuscular 
and neuropsychiatric OP syndromes [15]. 
 The WHO recommended pralidoxime regimen is  30 mg/kg bolus followed by   
 8 mg kg/hr infusion [1].Traditional dosing for pralidoxime in op poisoning is 1 gm every 
8 – 12 hrs  in adults and 25- 50 mg/ kg in children [22] 
Benzodiazepines:- 
Category: - antiepileptic, CNS depressant and anxiolytic. 
 It depresses all levels of CNS activities and is also used to treat OP – induced 
muscle fasciculations. 
Dose Regimen: Adults: 10 – 20 mg 1.V,  
  Elderly: 5-10mg/1V 
  Children: 0.2 -0.3 mg/kg I.V [15]. 
  
2.6.1 .EFFECT OF ORGANOPHOSPHORUS  COMPOUND ON PANCREAS :- 
          Various studies show that there is increased incidence of  Pancreatitis and its 
related complications after consumption of Organophosphorus compound when 
compared to general population. There is elevated serum Amylase level in these patients. 
 Though the exact mechanism  for its occurrence is not known , the following 
mechanisms have been suggested . 
a) OP insecticides  increase  the  intraductal pressure and exocrine pancreatic 
flow.The increase in  pressure leads to extravasation of pancreatic fluid. This 
increased pancreatic exocrine flow could be due to direct cholinergic 
hyperstimulation of pancreatic acinar and ductal cells .   
b) Experimental data supports the view that these organophosphate 
anticholineesterase compouds cause a functional ductal obstruction at the same 
time as stimulation of pancreatic exocrine secretion. 
c) There is pancreatic interstitial edema , acinar cell vacuolization , 
hyperamylasemia and hyperlipasemia following ingestion of OP poisoning. 
2.6.2 EFFECTS OF ORGANOPHOSPHOROUS COMPOUND  ON VARIOUS 
OTHER ORGANS :- 
  
1) Effects on the  Central Nervous System: 
 Complex changes in higher intellectual functions such as memory, problem 
solving and the interpretation of data. 
 Neuropsychological effects like impaired vigilance, reduced information 
processing and psychomotor speed, memory deficit, linguistic disturbances, 
depression, anxiety and irritability. 
2) Altered Immunity to Infection: 
 OP – induced immunosuppression was associated with severe cholinergic 
stimulation probably from a direct action of ACh upon the immune system or it may be 
secondary to the toxic chemical stress associated with cholinergic poisoning.  A marked 
impairment of neutrophil chemotaxis and greater frequency of upper respiratory tract 
infection was demonstrated in subjects exposed to OP in whom a significant decrease in 
both serum and RBC cholinesterase activity was observed. 
3) Change in Metabolism and endocrine activity:- 
The following changes have been observed in various studies 
a) Changes in glucose metabolism and in diurnal pattern of plasma ACTH 
b) Non ketotic hyperglycemia and glycosuria 
c) Significant decrease in serum T3 and T4 concentrations and increased levels of 
TSH. 
d) Damage to seminiferous tubules and to the principal cells in caput epididymis 
through its toxic effect on the leydig cells. 
 
4) Effects on cardiac function:- 
 Cardiac complications such as hypotension, hypertension, arrhythmias (Complete 
atrioventricular block, premature ventricular complexes, ‘torsade de pointes’ and cardiac 
arrest, often follow OP poisoning. 
 
5) Effect on Reproduction:- 
Op poisoning during pregnancy causes prenatal and postnatal death and congenital 
abnormalities such as vertebral deformities, limb defects polydactyly, intestinal hernia, 
cleft palate and hydroureter. 
 
6) Miscellaneous effects:- 
Inhibition of carboxyesterase enzymes especially, NTE, a brief bilateral vocal  
cord paralysis, arthritis, cerebellar disorder like ataxia [4]. 
 
2.7. STUDIES ON EFFECT OF OP COMPOUNDS ON SERUM AMYLASE 
LEVELS : 
   A prospective study was done by the Department of Internal Medicine, 
University of Yuzuncu Yil,Medical faculty,Van,Turkey in 2002[37] to find the 
prevalence of pancreatitis  in OP poisoning. Four of the total 47 patients with 
acute OP poisoning had obviously elevated Amylase and Lipase levels ( Amylase 
> 300 U/L ; Lipase >60 U/L). Only two of the patients with Amylase levels 
between 100 and 300 U/L Had elevated levels of Lipase. None of the patients 
with normal Amylase levels had elevated levels of Lipase. A total of 12.76% was 
diagnosed as acute Pancreatitis. It was concluded that acute Pancreatitis is not a 
rare complication of organophosphorus poisoning. In order to improve the 
outcome of OP poisoning early diagnosis of acute pancreatitis is important and 
serum Amylase and Lipase levels should be routinely considered carefully.  
   A prospective study was undertaken in PGIMER,CHANDIGARH, INDIA 
between June 2001-June 2005[38] to find the incidence of hyperamylasemia and 
acute pancreatitis in patients with OP poisoning. Of the 79 patients studied, serum 
Amylase was found to be elevated ( > 200 S.U) in 37 patients(46.95%). Among 
them in three patients it was 800 S.U. One of them showed swollen pancreas on 
ultrasonography and confirmed by CT. In other two patients, evidence of 
pancreatitis was not observed. There was no significant correlation between the 
nature of compounds ( OP or carbamates), duration and severity of cholinergic 
syndrome and  increase in serum Amylase. It has been concluded that mild 
elevation of serum Amylase is common in patients with OP poisoning, however 
acute Pancreatitis is rare. 
 A case was reported  by the Department of Internal Medicine ,Limassol General 
Hospital,Ciprus( dated 2005 March ) [39]regarding severe acute pancreatitis 
following N-Methyl carbamate insecticide ingestion. An 18 year old Caucasian 
man was admitted in ICU with Cholinergic crisis after ingestion of a carbamate 
insecticide. Two days after admission, an abdominal CT scan revealed  blurring of 
the peripancreatic fat planes, inflammation and swelling of pancreas, and 
substantial amount of ascitic fluid in the left anterior pararenal space and pelvis. 
Paracentesis and analysis of ascitic fluid demonstrated  findings suggestive of 
pancreatic ascites. There have been no other evident predisposing factors for acute 
pancreatitis other than carbamate intoxication. 11 days after admission repeat CT 
can revealed the formation of intrapancreatic fluid collection. Patient was 
discharged in good physical condition after two weeks of admission. The follow- 
up abdominal CT scan performed one month later showed a significant reduction 
in size of intrapancreatic fluid. Conclusion of the study was that acute pancreatitis 
was not uncommon after organophosphate intoxication and carbamates share the 
same risk as OP pesticides. 
 A retrospective study of medical records of 121 patients with the diagnosis of OP 
poisoning over three years was done in Veterans general hospital, National Yang-
Ming University in 1998[40]. Serum amylase , pancreatic amylase, salivary 
amylase, lipase and cholinesterase levels and the clinical manifestations were 
analyzed. It was observed that 44 patients (36%) had hyperamylasemia ( Amylase 
>360 U/L). Lipase was measured in 28 patients with hyperamylasemia ; nine of 
28 had hyperlipasemia (Lipase > 380 U/L). The finding of hyperamylasemia was 
closely related to clinical severity and presence of shock. It was concluded that 
hyperamylasemia is frequent in severe OP poisoning. However, hyperamylasemia 
is not synonymous with acute pancreatitis and pancreatic amylase is not reliable 
parameter in the diagnosis of organophosphate induced pancreatitis due to its low 
sensitivity and specificity. Lipase assay is indicated in patients with 
hyperamylasemia for early diagnosis of pancreatitis. 
 A case report published in 1994 by Moritz F et al ,Reanimation medicale, Rouen, 
France [41]: A 29 year old woman was admitted for ingestion of  carbamate 
insecticide. Cardiorespiratory arrest occurred at the second hour and acute 
necrotic hemorrhagic pancreatitis on the second day. Further evaluation was 
uneventful and the patient was discharged after 43 days. Carbamate intoxication 
was confirmed by high urinary Aldecarb metabolite concentrations. Hence, 
Carbamate pesticides carry the same risk as OP pesticides and should be 
monitored similarly. 
 Surgical gastroenterology department, South Africa reported two cases of severe 
acute pancreatitis complicated by pancreatic necrosis and retroperitoneal sepsis in 
1997[42]. Awareness of this complication should prompt earlier investigation 
because early diagnosis coupled with timely therapeutic measures may improve 
patients prognosis. 
 A retrospective study of OP poison in intensive care unit was performed to 
analyze the incidence of respiratory failure by Department of Anesthesiology & 
Critical care medicine, Kyodo general hospital , Ibaraki ,Japan[43] . Of the 32 op 
poisoning Patients, 16  developed respiratory failure and received ventilatory 
support . An increase in plasma Amylase above the normal range was found  in 
patients who developed respiratory failure. Thus in OP poisoning, the elevation of 
Amylase levels was predictive of subsequent respiratory failure. 
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3. AIM OF THE STUDY 
   
 
 
 
 
(i) To estimate serum Amylase levels in acute organophosphorus 
compound poisoning. 
(ii) To find out its relationship with 
a) clinical severity 
b) outcome 
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4. MATERIALS AND METHODS 
 
Subjects:  Patients presenting with Organophosphorous poisoning were the study 
subjects. 
 
Study design: A prospective cross - sectional study. 
 
Ethical committee approval: The Ethical committee approval was obtained to carry out  
the study in the hospital. 
 
Study setting:  Government Rajaji Hospital Madurai. 
Study duration: June 2007– June 2008 
Materials: 
           Of  a total of  145 patients with organophosphorus compound poisoning admitted 
to the hospital during the study period,40 were included in the study.  
Controls : 
            10 healthy (age matched) individuals were kept as control. 
Study criteria : 
Inclusion criteria: 
 40 patients with a history of exposure to OP poison were the study subjects. 
 
Exclusion criteria: 
• Patients with indication of exposure to a entirely different poison other than OP 
poison. 
• Patients with double poisoning  
• Patients who have consumed poison along with alcohol 
• Patients who are chronic alcoholics 
• Patients with history suggestive of gall stone disease 
• Patients with known history of lipid disorders 
• History suggestive of parotid gland disease 
• Patients with  history of lipid disorders 
• History suggestive of parotid gland disease 
• Patients with history of renal or hepatic disease 
• History of renal or hepatic disease 
• History of intake of drugs likely to produce pancreatitis –  
                           Azathioprine 
   6-Mercaptopurine 
   Thiazides 
   Frusemide 
   Pentamidine 
 
Study protocol:  
             Patients admitted  in GRH were the study group. A previously designed proforma 
was used to collect the demographic and clinical details of the patients. 
Collaborating department: 
 Department of Biochemistry, Madurai Medical College, Madurai 
 
 
Exposure assessment:  
 The following parameters were analyzed for association with OP pesticide 
exposure. 
• Demography 
  Age 
  Sex 
  Time of Admission 
  Economical Status 
  Familial Status 
  Reason for consumption 
• Poison Particulars 
  Severity grade 
  Symptoms after consumption 
  Immediate steps taken after OP exposure 
• Biochemical  evaluation  which includes Serum Amylase 
       Blood glucose, urea, creatinine and Liver function tests.      
•    Clinical Outcome ,Clinical Presentations  
     Pupil size, Pulse rate/min, Blood pressure, Respiratory rate/min, Secretions. 
Sample collection:  
                  40 Patients satisfying the inclusion criteria were selected for the study. About       
3 ml of venous blood were collected in two occasions from each subject first within 24 
hours of consumption of poison ( Sample I ) and next after 24 hours of first sample 
(Sample II ). The samples were centrifuged at 3000 rpm for 15 minutes. The supernatant 
serum was separated and freezed. Serum Amylase was estimated with the help of kit 
manufactured by Diasys Diagnostic Systems GmbH Alte S Strasse g 65558 Holyheim 
Germany by using CNP-G3 method Autoanalyser AUTOPAK. 
Limitations of this study : 
a) In this present study, patients were not subjected to CT / USG Abdomen because 
the study was limited to serum Amylase only. 
b) Autopsy study of pancreas was not done in the view of social limitation. 
c) Subsets of Amylase such as pancreatic and salivary Amylase was not estimated 
due to laboratory constraints. 
d) Urinary Amylase was not estimated due to technical limitations. 
e) Other biochemical parameters related to pancreatic involvement was not 
attempted due to financial constraints. 
STATISTICAL ANALYSIS : 
    Data analysis was done with the help of computer using Epidemiological 
Information Package (EPI 2002). 
    Using this software, frequencies, percentages, means, standard deviations, chi 
square and 'p'  values were calculated. Kruskul Wallis chi-square test was used to test the 
significance of difference between quantitative variables and Yate's  test  for qualitative 
variables. A 'p' value less than 0.05 is relationship.. 
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 5. OBSERVATION & RESULTS 
A. CHARACTERISTICS OF CASES STUDIED 
 
 
Table 1 : Age distribution 
 
 
Cases Controls Age Group 
No. % No. % 
Upto 20 years 5 12.5 1 10 
21-30 16 40 3 30 
31-40 14 35 4 40 
41 & above 5 12.5 2 20 
Total 40 100 10 100 
Mean 
S.D. 
32.3 yrs 
9.3 yrs 
 
29.9 yrs 
9.5 yrs 
‘p’ 0.3558 
Not significant 
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 Table 2 : Sex 
 
Cases Controls  
Sex No. % No. % 
Males 26 65 7 70 
Females 14 35 3 30 
‘p’ 0.5395 
Not significant 
 
                                                   SEX DISTRIBUTION 
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Table   3: Haematological parameters  
 
 
 
Cases 
 
Controls  
 
 
 
Parameter 
 
 
Mean 
 
S.D. 
 
Mean 
 
 
S.D. 
 
 
 
‘p’ 
Blood sugar 96.9 24.2 102.3 11.2 0.2535 
Not significant 
Blood urea 29.8 7.4 31.4 5.0 0.5035 
Not significant 
Serum Creatinine 0.95 0.3 0.83 0.21 0.281 
Not significant 
 
 
B. FEATURES OF POISONING 
Table  4 : Reason for poisoning  
 
Cases  
Reasons No. % 
Familial 26 65 
Financial 10 25 
Job stress 2 5 
Others 2 5 
Total 40 100 
 
                                      REASONS FOR POISONING 
 
26, 65%
10, 25%
2, 5% 2, 5%
FAMILIAL FINANCIAL JOB STRESS OTHERS
Table  5 : Mode of consumption   
 
Cases  
Mode of consumption No. % 
Water 27 67.5 
Milk 3 7.5 
Alone 10 25 
Others - - 
Total 40 100 
 
                                                 MODE OF CONSUMPTION 
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Table   6:  Agents  
 
Cases  
Agents No. % 
Methyl Parathion 21 52.5 
Bug killer liquid 6 15 
Fenthion 2 5 
Quinolphos 4 10 
Monocrotophos 2 5 
Chlorpyrifos 4 10 
Dichlorofos 1 2.5 
Total 40 100 
 
15%
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10%
5%
52%
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Table  7 :  Clinical features   
 
Cases  
Clinical features No. % 
Pinpoint pupil 22 55 
Depressed mental status 11 27.5 
Secretions 
i) Mild 
ii) Moderate 
iii) Severe 
iv) NS 
 
3 
24 
11 
2 
 
7.5 
60 
27.5 
5 
Fasciculation 12 30 
Heart Rate 
i) Bradycardia 
ii) Tachycardia 
iii) Normal 
 
17 
- 
23 
 
42.5 
- 
57.5 
Convulsions 1 2.5 
Respiratory Failure 10 25 
 
Table   8:  Outcome  
 
Cases  
Outcome No. % 
Alive 36 90 
Death 4 10 
 
10% 0%
0%
0%
90%
ALIVE DEATH
                 RELATIONSHIP BETWEEN INCREASED AMYLASE LEVELS                                                      
                  AND  OTHER FACTORS 
Table 9 : Increased Amylase levels in first 24 hours 
Normal 
 
Increased  
 
Amylase levels in 
 
 
 
 
No. 
 
% 
 
No. 
 
% 
Cases 15 37.5 25 62.5 
Controls 10 100 - - 
‘p’ 0.0015 
Significant 
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  Table  10 : Age and Amylase levels   
 
 
 
 
Amylase levels 
I II I – II 
 
 
 
 
 
Age group 
 
Mean 
 
S.D. 
 
Mean 
 
 
S.D. 
 
Mean 
 
S.D. 
Upto 20 years 132.8 155.7 44.8 44.8 88 111.6 
21-30 142.9 128.7 36.4 30.3 106.4 105.8 
31-40 162.6 135.1 46.4 35 116.1 112.7 
41 & above 94 28.6 30.8 22.4 63.2 17.5 
‘p’ 0.7042 
Not Significant 
0.744 
Not Significant 
0.7146 
Not Significant 
 
\ 
 
 
 
Table  11 : Sex and Amylase levels   
Amylase levels 
I II I – II 
 
 
 
 
Sex 
 
 
 
 
 
 
Mean 
 
S.D. 
 
Mean 
 
S.D. 
 
Mean 
 
S.D. 
Males 149.8 120.5 40.6 33.9 109.3 97.8 
Females 128.6 134.9 39.7 30.9 88.9 108.4 
‘p’ 0.321 
Not Significant 
0.876 
Not Significant 
0.3073 
Not Significant 
 
Table  12 : Mode of consumption and Amylase levels   
 
Amylase levels 
I II I – II 
 
 
 
 
Mode of 
consumption 
 
 
Mean 
 
S.D. 
 
Mean 
 
 
S.D. 
 
Mean 
 
S.D. 
Water 137.7 103.4 41.5 31.7 96.1 84 
Milk 41 27.2 15.3 3.8 25.7 25.7 
Alone 185.6 174.5 44.4 37.6 141.2 140.2 
‘p’ 0.0793 
Not Significant 
0.2074 
Not Significant 
0.0711 
Not Significant 
 Table  13 : Agents and Amylase levels   
 
Amylase levels 
I II I – II 
 
 
 
 
Agents 
 
 
Mean 
 
S.D. 
 
Mean 
 
 
S.D. 
 
Mean 
 
S.D. 
Methyl Parathion 150.4 157.4 39.3 35 111.1 127.5 
Bug killer liquid 125.2 98.5 44.5 39.4 80.7 85.6 
Fenthion 96 106.1 34.5 24.7 61.5 81.3 
Quinolphos 172.5 52.3 51.8 37.1 120.8 21.7 
Monocrotophos 148 141.4 45 46.7 103 94.8 
Chlorpyrifos 120 48.9 32.5 13.2 87.5 47.6 
Dichlorofos 128 - 22 - 106 - 
    
 
  
Table  14 : Clinical features and Amylase levels  
Amylase levels 
I II I – II 
 
 
Clinical features 
 
 
 
 
Mean 
 
S.D. 
 
Mean 
 
 
S.D. 
 
Mean 
 
S.D. 
Pinpoint pupil 
Present 
Absent 
 
204.1 
67 
 
136.1 
38.5 
 
52.4 
25.4 
 
33.2 
25.1 
 
151.1 
41.6 
 
111.8 
27.6 
‘p’ 0.0001 
Significant 
0.0009 
Significant 
0.0001 
Significant 
Depressed mental status 
Yes 
No 
 
261 
97.4 
 
151.8 
75.6 
 
63 
31.7 
 
31 
29 
 
198 
65.8 
 
131.1 
54.9 
‘p’ 0.0003 
Significant 
0.0023 
Significant 
0.0004 
Significant 
Secretions 
v) Mild 
vi) Moderate 
vii) Severe 
viii) NS 
 
83 
108.9 
242.2 
84.5 
 
59.2 
90.6 
157.5 
72.8 
 
30.3 
30.3 
59.7 
67.5 
 
25.7 
26.8 
32.3 
67.2 
 
52.7 
78.6 
182.5 
17 
 
33.8 
67.4 
135.2 
5.7 
‘p’ 0.0168 
Significant 
0.0219 
Significant 
0.0062 
Significant 
Fasciculation 
Present 
Absent 
 
272.3 
86.6 
 
149.9 
50.8 
 
67.5 
29 
 
33.4 
24.7 
 
204.8 
57.6 
 
127.2 
17.5 
‘p’ 0.0001 
Significant 
0.0001 
Significant 
0.0001 
Significant 
 
 
 
 Table  14 : Clinical features and Amylase levels (continued) 
 
Amylase levels 
I II I – II 
 
 
Clinical features 
 
 
 
 
Mean 
 
S.D. 
 
Mean 
 
 
S.D. 
 
Mean 
 
S.D. 
Heart Rate 
iv) Bradycardia 
v) Tachycardia 
vi) Normal 
 
209.1 
- 
93.3 
 
142.8 
- 
83.4 
 
51.1 
- 
33 
 
31.8 
- 
31.7 
 
157.9 
- 
60.4 
 
119.5 
- 
59.8 
‘p’ 0.0001 
Significant 
0.0321 
Significant 
0.0001 
Significant 
Convulsions 
Present 
Absent 
 
156 
142.1 
 
- 
126.9 
 
38 
40.3 
 
- 
32.9 
 
118 
101.7 
 
- 
102 
‘p’ - - - 
Respiratory Failure 
Yes 
No 
 
297.7 
90.6 
 
151.8 
50.8 
 
69.8 
30.4 
 
36.4 
24.6 
 
227.9 
60.2 
 
126.7 
37.3 
‘p’ 0.0001 
Significant 
0.0016 
Significant 
0.0001 
Significant 
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204.1
67
261
97.4
272.3
86.6
209.1
93.3
297.7
90.6
0
50
100
150
200
250
300
PINPOINT PUPIL FASCICULATION RES.FAILURE
PRESENT ABSENT
 Table  15 : Outcome and Amylase levels   
 
 
 
 
Amylase levels 
I II I – II 
 
 
 
 
 
Outcome 
 
Mean 
 
S.D. 
 
Mean 
 
 
S.D. 
 
Mean 
 
S.D. 
Alive 134.6 122 39.9 33.4 94.7 96.3 
Dead 213 142 44 25.3 169 130.7 
‘p’ 0.1762 
Not Significant 
0.443 
Not Significant 
0.1428 
Not Significant 
 
 RELATIONSHIP BETWEEN OUTCOME AND VARIOUS PARAMETERS 
 
 
Table 16 :  Age and outcome 
 
Alive 
 
Dead  
 
 
 
Age group 
 
 
No. 
 
% 
 
No. 
 
% 
Upto 20 years(5) 5 100 - - 
21-30(16) 13 81.3 3 18.2 
31-40(14) 13 92.9 1 7.1 
41 & above(5) 5 100 - - 
Mean 
S.D. 
30.4 years 
9.7 years 
25.5 years 
5.1 years 
‘p’ 0.2783 
Not Significant 
 
 
 
 
 
 
 Table   17: Sex and outcome   
 
Alive 
 
Dead  
 
 
Sex 
 
 
 
No. 
 
% 
 
No. 
 
% 
Male(26) 23 88.5 3 11.5 
Female(14) 13 92.9 1 7.1 
‘p’ 0.5619 
Not Significant 
 
Table   18: Reasons and outcome   
 
Alive 
 
Dead  
 
 
Reasons 
 
 
 
No. 
 
% 
 
No. 
 
% 
Familial(26) 22 84.6 4 15.4 
Financial(10) 10 100 - - 
Job stress(2) 2 100 - - 
Others(2) 2 100 - - 
 
Table   19: Agents and outcome   
 
Alive 
 
Dead  
 
 
Agents  
 
 
No. 
 
% 
 
No. 
 
% 
Methyl Parathion(21) 18 85.7 3 14.3 
Bug killer liquid(6) 6 100 - - 
Fenthion(2) 2 100 - - 
Quinolphos(4) 4 100 - - 
Monocrotophos(2) 1 50 1 50 
Chlorpyrifos(4) 4 100 - - 
Dichlorofos(1) 1 100 - - 
 
 
Table   20: Mode of consumption and outcome   
 
Alive 
 
Dead  
 
 
Reasons 
 
 
 
No. 
 
% 
 
No. 
 
% 
Water(27) 23 88.2 4 14.8 
Milk(3) 3 100 - - 
Alone(10) 10 100 - - 
 
  
Table   21: Haematological parameters and outcome 
 
Cases 
 
Controls  
 
 
 
Parameter 
 
 
Mean 
 
S.D. 
 
Mean 
 
 
S.D. 
 
 
 
‘p’ 
Blood sugar 97.2 23.5 94 33.7 0.5419 
Not Significant 
Blood urea 29.4 6.8 33 13.2 0.4976 
Not Significant 
Serum Creatinine 0.95 0.32 0.98 0.19 0.6578 
Not Significant 
 
 Table   22: Clinical parameters and outcome 
 
Outcome 
Alive Death 
 
 
Clinical features 
 
 
 
No. No. No. No. 
 
 
‘p’ 
Pinpoint pupil 
Present(22) 
Absent(18) 
 
18 
18 
 
81.8 
100 
 
4 
- 
 
18.2 
- 
 
0..8 
Not significant 
Depressed mental status 
Yes(11) 
No(29) 
 
7 
29 
 
63.6 
100 
 
4 
- 
 
36.4 
- 
 
0.0036 
Significant 
Secretions 
ix) Mild(3) 
x) Moderate(24 
xi) Severe(11) 
xii) NS(2) 
 
3 
24 
7 
2 
 
100 
100 
63.9 
100 
 
- 
- 
4 
- 
 
- 
- 
36.4 
- 
 
0.0001 
Significant 
Fasciculation 
Present(12) 
Absent(28) 
 
8 
28 
 
66.7 
100 
 
4 
- 
 
33.3 
- 
 
0.0054 
Significant 
 
 
 
 
 
 
 
 
 
  
Table  22 : Clinical features and Outcome (continued) 
 
Outcome 
Alive Death 
 
 
Clinical features 
 
 
 
No. % No. % 
 
‘p’ 
Heart Rate 
vii) Bradycardia(17) 
viii) Tachycardia(-) 
ix) Normal(23) 
 
13 
- 
23 
 
76.5 
- 
100 
 
4 
- 
- 
 
23.5 
- 
- 
 
0.026 
Significant 
Convulsions 
Present(1) 
Absent(39) 
 
- 
36 
 
- 
92.3 
 
1 
3 
 
100 
7.7 
 
0.1 
Not significant 
Respiratory Failure 
Yes(10) 
No(30) 
 
6 
30 
 
60 
100 
 
4 
- 
 
40 
- 
 
0.0023 
Significant 
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                                                          DISCUSSION 
 
 
 
 
 
 
6. DISCUSSION 
 
 
 Organophosphates and Carbamates are frequently used pesticides which can 
produce life-threatening intoxication. Well over 50,000 organophosphorous compounds 
have been synthesized since the first one by Clermont in 1857. All these compounds act 
by irreversible inactivation of acetylcholinesterase (ACh).  The clinical symptoms range 
from the classic cholinergic syndrome to flaccid paralysis and intractable seizures. About 
99% of fatal poisoning occurs in developing countries, particularly among farm workers.  
Despite an increased  incidence of  organophosphorous insecticide poisoning, the exact 
micro molecular changes that take place remain elusive.  Till date, atropine and oxime 
continue to occupy the prime position in the specific management of OP poisoning. 
 
 With the ease of availability, it is not surprising that the use of OP compounds in 
suicide attempts has mushroomed from a disturbing early trend to being one of the 
commonest modes of suicidal poisoning which accounted for 100% in our study.  This 
rate was consistent with the findings of Mahadi Balali Mood et al [38] (94.3%) whereas it 
was reported to be 67% by AM Saadeh et al [18]. There was no accidental exposure in our 
study.  This alarming incidence of suicidal attempts, may be probably because of the 
uncontrolled sale and use of these agents all over the country. 
 
Age, Gender Prevalence 
         The vast majority of poisonings followed oral ingestion of liquid form and almost 
for all the patients gastric lavage was immediately done.  The incidence was  higher 
(40%) in the age group of 21-30 followed by (35%)in the age group of  31-40. 
     These are consistent with the findings of Muhammet Guven et al [17] and  AM Saadeh 
et al [18] , where the mean ages were 24.1 and 23.95 respectively.   
 The most common reason for consumption in our study was found to be the 
familial stress (65%) followed by financial stress (25%). Methyl parathion accounted for 
about 52.5% of intoxication .The commonest mode of intake was found to be poison 
along with water (67.5%). 
Clinical symptoms 
 The accumulation of ACh in nerve terminals, results in continued stimulation with 
subsequent paralysis of receptors and accounts for the clinical signs of muscarinic, 
nicotinic and CNS effects. 
 Both the present study, and the study by Mahdi Balali-Mood et al [38], found 
association between the severity of poisoning and clinical manifestations.  The most 
marked muscarinic signs in our study population were, miosis (55%), excessive 
secretions (60%), and respiratory distress (25%).  The most prominent of the nicotinic 
effect is muscular end plate block, resulting in muscle weakness and fasciculations 
(30%).  The CNS symptoms, like depressed mental status was found in (27.5%) patients. 
Similar findings have also been reported by Murat Sungur et al [14]. 
 
Biochemical evaluation 
 The biochemical (Blood sugar, Serum creatinine & urea) results have not shown 
much variation from the normal levels in our study which was also indicated by Mahdi 
Balali-Mood et al [38]. 
  
 
Respiratory Depression 
 The most troublesome complication of OP poisoning was respiratory depression 
which could be due to reasons such as: aspiration of gastric contents, excessive 
secretions, pneumonia and septicemia complicating adult respiratory distress syndrome.   
Of the 40 patients, respiratory depression was observed in 10 (25%) cases.   
 
  Early recognition of respiratory failure, prompt endotracheal intubations and 
mechanical ventilation are life saving in severe OP poisoning. 
 
Serum Amylase levels in OP poisoning 
   OP insecticides  increase  the  intraductal pressure and exocrine  
pancreatic flow. The increase in  pressure leads to extravasation of pancreatic fluid. This 
increased pancreatic exocrine flow could be due to direct cholinergic hyperstimulation of 
pancreatic acinar and ductal cells .   
     In the study, the Amylase levels were significantly elevated at the time of admission 
[185.2 U/L] and have shown a gradual remission with proper treatment. The mean 
Amylase level in severely poisoned patients was 297.7 U/L  which was significantly  
(P < 0.01) higher  than the healthy control group.  
 
        On comparing the Amylase levels in first 24 hours against control, the variations 
were considered to be significant (P < 0.01). 
 
        From our observation, it can be suggested that estimation of Amylase levels would 
be extremely useful to assess the clinical severity . 
            Age and sex of the patients have no significant relationship with the amylase 
levels. The mean Amylase level in first 24 hours was 154 U/L which is significantly 
higher than the control groups.  
            In our study, there was no significant correlation between elevated Amylase levels 
and the outcome. From the observation we made, it could be suggested that OP pesticide 
poisoning is a serious condition that needs rapid diagnosis and treatment.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
 
 
 
 
 
 
 
 
 
 
 
                                                        CONCLUSION 
 
 
 
 
 
 
 
                                              7. CONCLUSION 
In India, Organophosphorus compounds cause more suicidal deaths among the 
earning  and nonearning members of the society. Of the 40 patients in our study 15 
patients (37.5%) had normal serum amylase level ; 25patients (62.5%) had elevated 
serum amylase level which is very significant. 
 
             From the observation we made, it could be suggested that OP pesticide poisoning 
is a serious condition that needs rapid diagnosis and treatment. The mean Amylase level 
in first 24 hours of OP poisoning  was 154 U/L which is significantly higher than the 
control groups. 
             The bad bedside prognostic factors which correlated very well with serum 
Amylase levels in the order of increasing severity include 
i) Convulsions  ( Amylase – 156 U/L) 
ii) Severe secretions    (242 U/L) 
iii) CNS depression      ( 261 U/L) 
iv) Fasciculations         (272U/L) 
v) Respiratory failure (297.7U/L) 
             Hence Serum amylase levels may be considered as a marker of 
Organophosphorous intoxication, since it enables the early recognition of severity and 
also helps to identify those at risk of developing the complications of  
Organophosphorous poisoning . 
             Our study also showed that there was a significant correlation between markedly 
elevated Amylase level and respiratory failure and therefore poor outcome. 
            A significant rise in Serum Amyase level also portends various complications that 
include convulsions , CNS depression, fasciculations and respiratory failure. 
 
However, as the study was limited to a small population due to financial and 
laboratory constraints, analysis of a larger group would definitely give an insight into the  
further finer relationship between serum amylase level and clinical severity and outcome 
in OP poisoning. 
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APPENDIX 
 
 
 
 
                                     
  
                                             PROFORMA 
 
NAME               :          IP NO : 
 
AGE / SEX        :       D.O.A : 
 
RESIDENCE      :    URBAN / RURAL                 D.O.D : 
 
OCCUPATION :  
 
INCOME           : 
 
TIME BETWEEN POISONING & ADMISSION : 
 
SUICIDAL / ACCIDENTAL / HOMICIDAL 
 
REASON : 
 
TREATMENT PRIOR TO ADMISSION : YES / NO 
 
POISON PARTICULARS : 
 
NAME OF POISON -  CHEMICAL NAME : 
 
    TRADE NAME         : 
 
QUANTITY CONSUMED          : 
 
NATURE OF POISON                  : LIQUID / POWDER / GRANULES 
 
MODE OF CONSUMPTION                        : 
 
IMMEDIATE STEPS TAKEN           : 
 
SYMPTOMS : 
 
   GIT: VOMITING 
 
 ABDOMINAL CRAMPS 
 
 ABDOMINAL PAIN / DISTENSION 
 
 DIARRHOEA 
 
CNS: ALTERED SENSORIUM 
 
 SEIZURES 
 
 BLURRING OF VISION 
 
         FASCICULATIONS ( TWITCHING ) 
 
         PARALYSIS ( WEAKNESS ) 
 
         BREATHLESSNESS 
 
OTHERS : SALIVATION / FROTHING 
 
         SWEATING 
 
         LACRIMATION 
 
PAST HISTORY : 
 
SIMILAR ATTEMPTS BEFORE        : YES / NO 
 
PREVIOUS PSYCHIATRIC ILLNESS : YES / NO 
 
COMORBID ILLNESS :  CARDIAC DISEASE  
 
       CHRONIC LUNG DISEASE 
 
       RENAL FAILURE 
 
       GALL STONE DISEASE 
 
       NEUROMUSCULAR DISEASE 
 
H/O DRUG INTAKE  
 
H/O JAUNDICE 
 
H/O RECENT SURGERY  
 
H/O ALCOHOL INTAKE 
 
CLINICAL  PROFILE  AT  THE TIME  OF  ADMISSION : 
 
CONSCIOUSNESS     PR : 
 
PUPIL SIZE      BP : 
 JAUNDICE      RR : 
CYANOSIS 
 
FASCICULATIONS 
 
CONVULSIONS 
 
RS : SECRETIONS 
 
        RESPIRATORY INSUFFICIENCY 
 
ABDOMEN : DISTENSION / TENDERNESS / PALPABLE MASS  
 
  BOWEL SOUNDS  + / -- 
 
INVESTIGATIONS : 
 
TC  
 
DC 
 
HB % 
 
ECG 
 
BLOOD  SUGAR :                  UREA :                                      CREATININE : 
 
LIVER FUNCTION TESTS : SR.BILIRUBIN – TOTAL :           DIRECT :             
 
INDIRECT: 
             SGOT :                                         SGPT:                 ALP: 
 
            PROTEIN-TOTAL:                       ALBUMIN:         GLOBULIN: 
 
SERUM AMYLASE :  I : 
 
   II : 
 
COMPLICATIONS: 
 
RESPIRATORY FAILURE      HYPOTENSION 
 
HYPOKALEMIA     PANCREATITIS 
 
ARRYTHMIAS     HEPATOCELLULAR  JAUNDICE 
 
DURATION OF HOSPITALIZATION : 
 
FINAL  OUTCOME :  FULL RECOVERY                     PARTIAL                         DEATH 
 
  
MASTER CHART 
Clinical Features 
Amylase 
Levels 
(IU/L) 
 
Bl.S 
 
 
 
Bl.U 
 
Bl.C 
 
Out 
come 
S. 
No Age Sex 
Type 
of 
Expo 
sure 
Reason Agents 
Mode of 
Consum 
ption 
P M S F H C RF 
 
  I 
 
  II 
Mg% Mg% Mg%  
1 20 M I Fa MP W + - ++ + N - + 397 117 109 35 0.9 Alive 
2 32 M I Fi B W - - NS - N - - 136 115 79 42   1.3 Alive 
3 22 M I Fa MP W + + +++ + B - + 391 43 84 16 0.7 Dead 
4 33 M I Fa F M - - ++ - N - - 21 17 88 19 1 Alive 
5 24 F I Fa MP W + + +++ + B + + 156 38 63 32 1 Dead 
6 35 M I Fi C W + + +++ + B - + 188 30 72 22 0.6 Alive 
7 24 F I Fa MP      W - - ++ - N - - 15 10 68 30 0.7 Alive 
8 24 M I Fa D W + - ++ - B - - 128 22 102 21 1.1 Alive 
9 31 F I Fa MP W - - ++ - N - - 37 12 98 32 0.8 Alive 
10 22 M I Fa B W + - ++ - N - - 112 22 68 31 1.5 Alive 
11 35 F I Fi C M + - ++ - B - - 72 18 76 28 0.6 Alive 
12 42 M I Fa MP W - - ++ - N - - 98 15 64 25 1.5 Alive 
13 
 23 M I Fa MP W + + +++ + B - + 57 17 87 48 1.1 Dead 
14 16 F I Fa B W - - NS - N - - 33 20 72 24 0.8 Alive 
15 29 F I Fi Q W + + +++ + B - + 213 90 114 36 0.6 Alive 
16 32 F I Fa MP A + + +++ + B - + 529 100 142 38 1.2 Alive 
17 25 M I Fa MP W - - ++ - N - - 75 19 96 25 0.5 Alive 
18 35 M I O MP W - - ++ - N - - 87 32 108 38 0.8 Alive 
19 31 F I Fi Q W + - ++ - N - - 217 77 60 20 0.9 Alive 
20 16 F I Fa MP W - - + - N - - 151 60 106 25 0.7 Alive 
21 45 M I Fa MO A + - ++ - B - - 48 12 98 32 1.1 Alive 
22 55 M I Fa MP A + + +++ + B - - 120 60 72 23 0.9 Alive 
23 38 M I Fa MP W - - - - N - - 55 15 82 36 1.3 Alive 
24 25 F I Fi B W - - ++ - N - - 63 24 100 22 0.8 Alive 
25 35 F I Fa F A + + +++ + B - - 171 52 110 38 1.3 Alive 
26 25 F I Fa MP W - - ++ - N - - 70 28 88 26 0.6 Alive 
27 30 M I Fa MP W + - ++ - B - - 178 70 98 30 1.1 Alive 
28 23 F I Fi MP W - - + - N - - 43 16 94 32 0.7 Alive 
29 40 M I Fa B W + + ++ + B - + 312 68 60 25 0.9 Alive 
30 38 M I Fa B A + - ++ - N - - 95 18 126 36 1.4 Alive 
31 17 F I Fi MP M - - ++ - N - - 30 11 104 40 1.8 Alive 
32 23 M I J C A + - +++ - B - - 105 32 140 17 0.6 Alive 
33 21 M I Fi MP A - - ++ - N - - 42 13 98 34 0.6 Alive 
34 16 M I Fa MP W - - ++ - N - - 53 16 98 18 0.8 Alive 
35 25 M I J Q A + - ++ - B - - 152 22 106 34 1.2 Alive 
36 33 M I Fa MO W + + +++ + B - + 248 78 142 36 1.1 Dead 
Clinical Features 
Amylase 
Levels 
(IU/L) 
 
Bl.S 
 
 
 
Bl.U 
 
Bl.C 
 
Out 
come 
S. 
No Age Sex 
Type 
of 
Expo 
sure 
Reason Agents 
Mode of 
Consum 
ption 
P M S F H C RF 
 
  I 
 
  II 
Mg% Mg% Mg%  
37 45 M I Fi C W + - ++ - N - - 115 50 120 36 0.8 Alive 
38 52 M I Fa MP W  - - ++ -  N  - - 89 17 130 28 O.6 Alive 
39 28 M I O MP A + + +++ + B - + 486 117 156  32 1 Alive 
40 31 M I Fa Q A - - ++ - N - - 
108 18 98 30 0.8 Alive 
 
 
41 35 M Control - - - - - - - - - -  32  84 30 0.8  
42 44 F Control - - - - - - - - - - 24  110 36 1  
43 25 M Control - - -- -- - - - - - - 28  96 38 1.1  
44 33 M Control - -- - -- - - - - - -- 36  108 28 0.6  
45 50 M Control - - - - - - - - - - 26  117 38 1.2  
46 19 F Control - - - - - - - - - - 22  86 28 0.6  
47 26 M Control - - - - - - - - - - 35  98 26 0.8  
48 32 M Control - - - - - - - - - - 40  110 24 0.6  
49 34 F Control -- - -- - - - - - - - 45  102 34 0.8  
50 25 M Control  -- - - - - - - - - 46  112 32 0.8  
 
       
 
 
 
 
 
 
 
 
ABBREVIATIONS : 
 
TYPE OF EXPOSURE 
 
 I - INTENTIONAL  
 A - ACCIDENTAL 
 
REASON FOR CONSUMPTION 
 
 Fa  - Familial 
Fi - Financial 
J - Job stress 
O -  Others 
MODE OF CONSUMPTION 
            W - Water 
M - Milk 
A - Alone 
O - Others 
AGENTS 
 
Mp - Methyl parathion 
B - Bug killer liquid 
F - Fenthion 
Q - Quinolphos 
Mo - Monocrotophos 
C - Chlorpyrifos 
D - Dichlorofos 
 
CLINICAL FEATURES 
 
 P - Pinpoint pupil 
M - Depressed Mental Status 
S - Secretions      +    Mild 
              ++ Moderate 
           +++ Serere 
F - Fasciculation  
H - Heart Rate - B – bradycardia 
    - T – Tachycardia 
     - N – Normal 
C - Convulsions 
RF - Respiratory failure 
 
Bl.S - Blood Sugar 
Bl.U    -           Blood Urea 
Sr.C     -           Serum Creatinine 
